A patient with the novel coronavirus disease COVID-19 saw symptoms improve after being treated with Sanofi’s immune modulator Plaquenil (hydroxychloroquine sulfate), according to the latest report posted on the website of the Japanese Association for Infectious Diseases.
The report posted on March 10 details the clinical course followed by a 69-year old man who was given Plaquenil, among other drugs, without disclosing the name of the institutions that treated him. The patient, who is on dialysis, was also given several antibiotics and the anti-flu agent Rapiacta (peramivir) before receiving Plaquenil. The report pointed out that while it is possible that the antibiotics and Rapiacta helped improve his symptoms, and also that the body fluid management through dialysis might have paid off, it is most likely that the use of Plaquenil led to the improvement.
In the past, Plaquenil was used as a treatment for SARS (severe acute respiratory syndrome), and for COVID-19, its use and clinical efficacy has been reported in China.
Read the original article here: https://pj.jiho.jp/article/